We have an extreme potential for growth. It's hard to predict what this thing will do.

It has the potential for exponential growth. We'll know in the next 12 hours if this is going to be a major problem.

The growing complexity of our customers' environments has imposed an artificial ceiling on their growth potential,

Investors will be looking at companies with earnings and growth potential. They're not going to wait two years for drug discovery and four years for product development. And that leaves a lot of biotech companies off the radar.

The pace of this growth will slow down, but probably not until we approach 2008.

We've been very lucky, but we're not out of the woods by any stretch of the imagination.